Latest news with #NVIDIABioNeMo
Business Wire
12-06-2025
- Business
- Business Wire
Sensible Biotechnologies Slashes Time Taken to Optimize Novel Cell-Based mRNA Therapeutics by More Than 90% with AI Platform Built on NVIDIA Technology
BOSTON--(BUSINESS WIRE)-- Sensible Biotechnologies, a biotechnology company pioneering a cell-based platform for the design and manufacturing of mRNA therapeutics, today announced an initiative to accelerate the development of next-generation mRNA medicines through AI-driven molecular design powered by NVIDIA accelerated computing and AI. 'By combining our cell-based platform with NVIDIA accelerated computing and AI, we're laying the foundation for programmable, high-performance RNA medicines.' Miroslav Gasparek, CEO and co-founder of Sensible Biotechnologies. Sensible has developed a unique design, optimization, and manufacturing process for producing mRNA drugs within living cells. The mRNA platform, which can include a range of novel modifications, creates a pure and low-immunogenicity drug product, unlocking new therapeutic areas with safe, effective, affordable and repeatable mRNA therapeutics. This replaces traditional in vitro transcription methods, which are unable to meet the demands of next-generation therapies for cancer, rare diseases, gene editing, and other unmet medical needs. To enable predictive and precise mRNA sequence design, Sensible's proprietary closed-loop AI-powered design and optimization platform models RNA folding from raw sequence to stable conformation. It integrates NVIDIA technology, including NVIDIA BioNeMo framework and NVIDIA NIM microservices on the NVIDIA DGX Cloud platform with NVIDIA Hopper GPUs, to apply physics-based simulations and machine learning to understand how RNA folds and behaves in complex biological environments. Using DGX Cloud with NVIDIA H100 80 GB and double-precision performance, Sensible achieves over 11,000 simulation steps per second. This performance enables the team to screen multiple RNA candidates in parallel, reducing simulation runtimes from overnight to under an hour per sequence. By incorporating NVIDIA technology, Sensible has cut its mRNA optimization cycles from 15 days to just one – a reduction of more than 90%. This efficiency enables faster iteration and informed sequence optimization, giving Sensible the ability to rapidly manipulate mRNA design space and advance the next generation of life-saving medicines. 'Producing therapeutic mRNA inside living cells requires solving intricate biological problems, from RNA folding to packaging,' said Krishna Motheramgari, PhD, Principal Computational Scientist at Sensible Biotechnologies. 'With advanced NVIDIA accelerated computing and AI, we can simulate these dynamics rapidly and accurately, accelerating our design cycle dramatically.' 'This technology integration brings us closer to our vision of rationally designed mRNA therapeutics,' said Miroslav Gasparek, Chief Executive Officer and co-founder of Sensible Biotechnologies. 'By combining our cell-based platform with NVIDIA accelerated computing and AI, we're laying the foundation for programmable, high-performance RNA medicines.' About Sensible Biotechnologies, Inc. Sensible Biotechnologies is developing the first cell-based platform for the design, optimization, and manufacturing of highly functional, low-immunogenic mRNA, unlocking the therapeutic potential of mRNA for pharma and biotech partners across a wide range of applications. Based in Boston, Oxford and Bratislava, Sensible has raised more than $13M from leading life science and deep tech investors, including Recode Ventures, BlueYard Capital, Kaya VC, Backed VC, Y Combinator, ZAKA VC, and Onsight – the VC fund founded by the co-founder of BioNTech, Christoph Huber, and the co-founder of ARM, Hermann Hauser.
Yahoo
19-03-2025
- Science
- Yahoo
Sapio Sciences Makes AI-Native Drug Discovery Seamless with NVIDIA BioNeMo
Integration of the NVIDIA BioNeMo platform enhances AI capabilities across the drug discovery lifecycle BALTIMORE, March 19, 2025--(BUSINESS WIRE)--Sapio Sciences, the science-aware™ lab informatics platform, today announced the integration of the NVIDIA BioNeMo platform into the Sapio Lab Informatics Platform. This integration brings AI-driven computational drug discovery directly into Sapio ELN (Electronic Lab Notebook), helping to streamline workflows and improve decision-making in drug discovery. With the BioNeMo platform, researchers can accelerate drug discovery by leveraging science-specific AI frameworks, pre-trained models, and generative AI tools to streamline the identification of potential drug candidates and improve target selection accuracy. NVIDIA BioNeMo provides scientists with a framework for training and deploying large biomolecular language models at supercomputing scale. The integration of BioNeMo into the Sapio Platform provides scientists with embedded in silico tools, enabling them to, for example, generate novel candidate molecules early in the research process and test their docking with a target protein. With AI-driven molecular simulations available within a single, unified workflow, researchers can streamline their processes, enhance innovation, and accelerate the transition from discovery to development. Within Sapio ELN, researchers can access BioNeMo NIM microservices to rapidly identify and optimize drug candidates using AI-driven molecular modeling, including AlphaFold2 NIM for predicting accurate 3D protein structures; MoIMIM NIM to enable the design and optimization of small molecules; and DiffDock NIM, an AI-powered docking model developed by MIT. These models provide scientists with easy access to AI-driven tools without extensive setup, ensuring faster, more efficient research workflows. Kevin Cramer, Founder, CEO & CTO at Sapio Sciences, commented: "AI innovation is advancing rapidly, but scientists are often forced to navigate fragmented tools with complex interfaces, slowing down research. Our integration of NVIDIA's powerful AI-driven tools directly into the Sapio Platform enables researchers to apply AI seamlessly into their experiments. Through this work, we are removing inefficiencies and equipping scientists with the tools to rapidly generate, analyze, and visualize both chemical and biological results." Kevin continued: "We are working with NVIDIA to equip scientists and researchers with the most advanced AI tools to drive innovation in life sciences. This collaboration is a major step toward making AI an integral part of the drug discovery process, helping researchers make faster, data-driven decisions and improve research outcomes." Anthony Costa, Director, Digital Biology at NVIDIA, commented: "Integrating BioNeMo into Sapio's AI-driven research platform gives scientists access to advanced generative AI models for drug discovery. With AlphaFold2, MoIMIM, and DiffDock NIMs, researchers can predict, optimize, and validate drug candidates with greater speed and accuracy. This work underscores AI's growing role in transforming pharmaceutical research and accelerating the path to breakthrough treatments." Integrating NVIDIA technologies into the Sapio Platform is one of the many ways Sapio Sciences is helping to improve and accelerate biopharma discovery, clinical diagnostics, and drug manufacturing. Find out more about the Sapio/NVIDIA integration here. About Sapio Sciences At Sapio Sciences, our mission is to improve lives by accelerating the entire drug lifecycle. Our cloud-based solutions—LIMS, ELN, and Scientific Data Management—are unified on a flexible, configurable, and AI-powered informatics platform, streamlining complex workflows, unifying scientific data, and enabling faster, smarter decisions across biopharma research and development, clinical diagnostics, and manufacturing. Trusted by global leaders and innovators worldwide, we support a wide range of best-in-class applications, from NGS and bioanalysis to bioprocessing, stability studies, histopathology, antibody discovery, and in vivo studies. Discover how Sapio Sciences can revolutionize your lab operations at and follow us on LinkedIn. View source version on Contacts Media contacts: Zyme Communications Anna BakewellTel: +44 (0)7801 098 242Email: Tim BrookHead of PR, Sapio SciencesTel: +44 (0)7760 766 213Email: press@
